|Day Low/High||21.64 / 22.08|
|52 Wk Low/High||19.25 / 28.60|
INDEPENDENCE MIS™ enhances the ALIF surgical technique by offering fewer procedural steps and a less invasive surgical corridor than traditional integrated spacers
QUARTEX™ Occipito-Cervico-Thoracic (OCT) Stabilization System is a threaded screw and rod platform offering true thoracic pedicle screws with diameters up to 5.5 mm, allowing surgeons to take full advantage of varying spinal anatomy.
Investors in Globus Medical Inc saw new options become available today, for the November 18th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the GMED options chain for the new November 18th contracts and identified one put and one call contract of particular interest.
Trade-Ideas LLC identified Globus Medical (GMED) as a "dead cat bounce" (down big yesterday but up big today) candidate
Here are Wednesday's top research calls, including upgrades for Coach and Alaska Air, and downgrades for Southwest Airlines and Twitter.
These five technical setups are showing solid upside potential right now.
The health care sector is booming, but many stocks are overvalued. We pinpoint the best buys now in the medical device niche.
These medical device makers could be acquisition targets (and one buyer) following Zimmer Biomet's takeout of LDR Holding. Their charts are also buys, says technical chartist Bruce Kamich.
The $1 billion transaction could inspire other medical device companies and private equity firms to bend over backwards for spinal device assets.
Looking at options trading activity among components of the Russell 3000 index, there is noteworthy activity today in Globus Medical Inc , where a total volume of 3,046 contracts has been traded thus far today, a contract volume which is representative of approximately 304,600 underlying shares (given that every 1 contract represents 100 underlying shares). That number works out to 54.1% of GMED's average daily trading volume over the past month, of 563,450 shares.
The hefty premium Zimmer Biomet is paying in the $1 billion deal for the spine company suggests the target's management followed a competitive process.
Globus Medical (GMED) coverage was started with an ‘equal weight’ rating and $26 price target at Barclays.
Here are Monday's top research calls, including upgrades for J.C. Penney and Nokia, a downgrade for Kohl's and new coverage of Microsoft.
Trade-Ideas LLC identified Globus Medical (GMED) as a weak on high relative volume candidate
Investors in Globus Medical Inc saw new options become available this week, for the May 20th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the GMED options chain for the new May 20th contracts and identified one put and one call contract of particular interest.